Research Article
Maintenance Therapy with FOLFIRI after FOLFIRINOX for Advanced Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis
Table 1
Characteristics of study participants (n = 22).
| | Age (years) | | | Mean | 59.0 | | Median | 60.5 | | Range | 37–74 |
| | Sex (no./%) | | | Female | 12/55% | | Male | 10/45% |
| | ECOG performance status score (no./%) | | | 0 | 17/77% | | 1 | 5/23% |
| | Pancreatic tumor location (no./%) | | | Head | 11/50% | | Body | 7/32% | | Tail | 4/18% |
| | Biliary stent (no./%) | | | Yes | 3/14% | | No | 19/86% |
| | Pancreaticoduodenectomy (no./%) | | | Yes | 7/32% | | No | 15/68% |
| | Indication for cytostatic therapy (no./%) | | | Primary locally inoperable | 3/14% | | Primary metastasized | 12/55% | | Local recurrence after PD | 5/23% | | Metastatic recurrence after PD | 2/9% |
| | Known chronic diseases (no./%) | | | Medically treated hypertension | 12/55% | | Diabetes type II | 6/27% | | COPD | 3/14% | | Renal insufficiency > WHO I° | 4/18% |
|
|
